SciBase News

First Patient in New Study Assessing early prediction of flares

Navigator — Tue, 23 Jun 2026 15:33:37 GMT

The primary objective of the multicenter prospective clinical study is to assess the prediction of flares in atopic dermatitis (AD). This milestone marks a significant step forward in understanding and managing this chronic, inflammatory skin condition, which affects millions of people worldwide.

The study, titled DETECT-AD, the first study through the collaboration with Castle Biosciences, will investigate SciBase method of Electrical Impedance Spectroscopy (EIS) ability to predict the onset of flares in patients with atopic dermatitis. By identifying early signs, the research aims to enable proactive interventions, improve patient quality of life, and reduce the burden of unpredictable flare-ups.

Atopic dermatitis is characterized by periods of remission and flare-ups, which can significantly impact patients' daily lives. Current treatment approaches are often reactive, addressing symptoms only after they appear. This study seeks to shift the paradigm toward proactive, personalized care, empowering patients and healthcare providers with actionable insights.

"The enrollment of the first patient is an exciting milestone in our mission to transform the management of atopic dermatitis. By predicting flares before they occur, we hope to offer patients greater control over their condition and improve their overall well-being", said Pia Renaudin, CEO of SciBase.,

For further information please contact:

Pia Renaudin, CEO,

Phone. +46732069802

E-mail: pia.renaudin@scibase.com

Certified Advisor (CA):

DNB Carnegie Investment Bank AB (publ)

Tel: +46 8 588 68 570

E-mail: certifiedadviser@carnegie.se

About SciBase and Nevisense
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

--------------------------------------------------------------------------------------

PR 1st patient in

SciBase reaches milestone with over 400,000 tests sold with Nevisense

Navigator — Wed, 17 Jun 2026 05:47:42 GMT

Nevisense is the only FDA-approved and CE-marked non-invasive diagnostic technology used by dermatologists to evaluate suspicious moles and assess a patient's individual risk of melanoma. By providing more accurate and personalized insights at the point of care, it supports better clinical decision-making.

Although Nevisense is currently primarily used to detect skin cancer, both malignant melanoma and NMSC (Non-melanoma skin cancer), we are seeing an increased interest in the skin barrier. After the end of 2025, a new clinical study was published showing that Nevisense can predict the development of atopic dermatitis in newborns. This is very promising as we have several larger studies for this indication underway. An important milestone for us regarding the development of using Nevisense to diagnose dermatological diseases is the collaboration we entered with Castle Biosciences in 2025. Through the agreement, we open up exciting opportunities for new indications.

"Another key milestone - with each Nevisense test, we empower clinicians to make more informed and precise early detection decisions, ultimately improving patient outcomes, " said Pia Renaudin, CEO, SciBase.

For further information, please contact:

Pia Renaudin, CEO

Phone: +46 73 206 98 02

Email: pia.renaudin@scibase.com

Certified Advisor (CA):
DNB Carnegie Investment Bank AB (publ)

Tel: +46 8 588 68 570

Email: certifiedadviser@carnegie.se

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

--------------------------------------------------------------------------------------

PR 400k

Test entry

Navigator — Sat, 23 May 2026 14:18:22 GMT

some text...